
4. A compound which is *N*-(3-(2-(dimethylamino)ethoxy)-5-(trifluoromethyl)phenyl)-2-(4-(4-ethoxy-6-oxo-1,6-dihydropyridin-3-yl)-2-fluorophenyl)acetamide, represented by Formula (II):



(II).

5. The pharmaceutically acceptable salt of the compound according to claim 1 which is selected from the group consisting of the hydrochloric acid salt, aspartic acid salt, hippuric acid salt, and phosphoric acid salt.

6. The pharmaceutically acceptable salt of the compound according to claim 1 which is the hydrochloric acid salt.

7. The pharmaceutically acceptable salt according to claim 5 or claim 6 which is in crystalline form.

8. A pharmaceutical composition comprising the compound or pharmaceutically acceptable salt according to any one of claims 1-7 and a pharmaceutically acceptable excipient.

9. A method of treating irritable bowel syndrome comprising administering to a human in need thereof an effective amount of the compound or pharmaceutically acceptable salt according to any one of claims 1-7.

10. A method of treating cancer comprising administering to a human in need thereof an effective amount of the compound or pharmaceutically acceptable salt according to any one of claims 1-7.

11. The compound or pharmaceutically acceptable salt according to any one of claims 1-7 for use in therapy.


12. The compound or pharmaceutically acceptable salt according to any one of claims 1-7 for use in the treatment of irritable bowel syndrome.

13. The compound or pharmaceutically acceptable salt according to any one of claims 1-7 for use in the treatment of cancer.

14. Use of the compound or pharmaceutically acceptable salt according to any one of claims 1-7 in the preparation of a medicament for the treatment of irritable bowel syndrome.

15. Use of the compound or pharmaceutically acceptable salt according to any one of claims 1-7 in the preparation of a medicament for the treatment of cancer.

4. A compound which is *N*-(3-(2-(dimethylamino)ethoxy)-5-(trifluoromethyl)phenyl)-2-(4-(4-ethoxy-6-oxo-1,6-dihydropyridin-3-yl)-2-fluorophenyl)acetamide, represented by Formula (II):



(II).

5. The pharmaceutically acceptable salt of the compound according to claim 1 which is selected from the group consisting of the hydrochloric acid salt, aspartic acid salt, hippuric acid salt, and phosphoric acid salt.

6. The pharmaceutically acceptable salt of the compound according to claim 1 which is the hydrochloric acid salt.

7. The pharmaceutically acceptable salt according to claim 5 or claim 6 which is in crystalline form.

8. A pharmaceutical composition comprising the compound or pharmaceutically acceptable salt according to any one of claims 1-7 and a pharmaceutically acceptable excipient.

9. The compound or pharmaceutically acceptable salt according to any one of claims 1-7 for use in therapy.

10. The compound or pharmaceutically acceptable salt according to any one of claims 1-7 for use in the treatment of irritable bowel syndrome.

11. The compound or pharmaceutically acceptable salt according to any one of claims 1-7 for use in the treatment of cancer.

12. Use of the compound or pharmaceutically acceptable salt according to any one of claims 1-7 in the preparation of a medicament for the treatment of irritable bowel syndrome.

13. Use of the compound or pharmaceutically acceptable salt according to any one of claims 1-7 in the preparation of a medicament for the treatment of cancer.